While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...
Bloomberg News Now is a comprehensive audio report on today's top stories. Listen for the latest news, whenever you want it, covering global business stories around the world.
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to ...
2d
Hosted on MSNBarclays Downgrades Moderna (MRNA)Fintel reports that on February 18, 2025, Barclays downgraded their outlook for Moderna (NasdaqGS:MRNA) from Overweight to ...
Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...
The FDA is mired in uncertainty with some staffers losing their jobs over the weekend and more potentially to come, vaccines ...
2d
Hosted on MSNModerna: A Generational Opportunity for Investors in 2025As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company ...
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results